Carna Biosciences Management

Management Kriterienprüfungen 2/4

Carna Biosciences CEO ist Kohichiro Yoshino , ernannt in Apr 2003, hat eine Amtszeit von 21.58 Jahren. besitzt direkt 1.75% der Aktien des Unternehmens, im Wert von ¥105.18M . Die durchschnittliche Betriebszugehörigkeit des Managementteams und des Verwaltungsrats beträgt 12.8 Jahre bzw. 6.8 Jahre.

Wichtige Informationen

Kohichiro Yoshino

Geschäftsführender

n/a

Gesamtvergütung

Prozentsatz des Geschäftsführergehalts	n/a
Amtszeit als Geschäftsführer	21.6yrs
Eigentum des Geschäftsführers	1.7%
Durchschnittliche Amtszeit des Managements	12.8yrs
Durchschnittliche Amtszeit der Vorstandsmitglieder	6.8yrs

Jüngste Management Updates

Recent updates

Carna Biosciences, Inc. (TSE:4572) Shares May Have Slumped 26% But Getting In Cheap Is Still Unlikely

Aug 06

What Carna Biosciences, Inc.'s (TSE:4572) P/S Is Not Telling You

Apr 17

Health Check: How Prudently Does Carna Biosciences (TYO:4572) Use Debt?

Apr 11

How Much Did Carna Biosciences'(TYO:4572) Shareholders Earn From Share Price Movements Over The Last Five Years?

Feb 17

Health Check: How Prudently Does Carna Biosciences (TYO:4572) Use Debt?

Dec 26

Geschäftsführer

Kohichiro Yoshino (75 yo)

21.6yrs

Amtszeit

Dr. Kohichiro Yoshino, Ph. D. is Independent Outside Director of Kringle Pharma, Inc since December 2018. Dr. Yoshino serves as the Chief Executive Officer of Carna Biosciences, Inc. He has been President...

Führungsteam

Name	Position	Amtszeit	Vergütung	Eigentümerschaft
Kohichiro Yoshino	CEO, President & Representative Director	21.6yrs	keine Daten	1.75% ¥ 105.2m
Emi Yamamoto	GM of Business Mgt.	9.2yrs	keine Daten	0.29% ¥ 17.2m
Masaaki Sawa	GM of Research & Development Division	no data	keine Daten	0.56% ¥ 33.4m
Norio Aikawa	Head of Drug Discovery & Support Business	16.3yrs	keine Daten	0.53% ¥ 32.1m
Akinori Arimura	GM of Clinical Development	5.8yrs	keine Daten	0.086% ¥ 5.2m

12.8yrs

Durchschnittliche Betriebszugehörigkeit

61yo

Durchschnittliches Alter

Erfahrenes Management: 4572Das Führungsteam des Unternehmens verfügt über eine langjährige Erfahrung (12.8 ).

Vorstandsmitglieder

Name	Position	Amtszeit	Vergütung	Eigentümerschaft
Kohichiro Yoshino	CEO, President & Representative Director	21.6yrs	keine Daten	1.75% ¥ 105.2m
Emi Yamamoto	GM of Business Mgt.	8.7yrs	keine Daten	0.29% ¥ 17.2m
Masaaki Sawa	GM of Research & Development Division	9.7yrs	keine Daten	0.56% ¥ 33.4m
Norio Aikawa	Head of Drug Discovery & Support Business	20.7yrs	keine Daten	0.53% ¥ 32.1m
Akinori Arimura	GM of Clinical Development	1.7yrs	keine Daten	0.086% ¥ 5.2m
Tsuguo Ogasawara	Independent Outside Director	4.8yrs	keine Daten	0.026% ¥ 1.6m
Atsuo Arita	Independent Outside Director	4.8yrs	keine Daten	0.042% ¥ 2.5m
Teruo Takayanagi	Independent Outside Director	9.7yrs	keine Daten	0.0058% ¥ 346.5k
Takao Matsui	Independent Outside Director	4.8yrs	keine Daten	keine Daten
Kaoru Suzuki	Independent Outside Director	less than a year	keine Daten	keine Daten

6.8yrs

Durchschnittliche Betriebszugehörigkeit

75yo

Durchschnittliches Alter

Erfahrener Vorstand: 4572Die Vorstandsmitglieder gelten als erfahren (6.8 Jahre durchschnittliche Amtszeit).

Carna Biosciences Management

Management Kriterienprüfungen 2/4

Wichtige Informationen

Jüngste Management Updates

Carna Biosciences, Inc., Annual General Meeting, Mar 26, 2024

Carna Biosciences, Inc., Annual General Meeting, Mar 24, 2023

Insufficient new directors

Carna Biosciences, Inc., Annual General Meeting, Mar 24, 2022

Carna Biosciences, Inc., Annual General Meeting, Mar 25, 2021

Recent updates

Third quarter 2024 earnings released: JP¥27.37 loss per share (vs JP¥20.13 loss in 3Q 2023)

Carna Biosciences, Inc. to Report Q3, 2024 Results on Nov 08, 2024

Carna Biosciences, Inc. (TSE:4572) Shares May Have Slumped 26% But Getting In Cheap Is Still Unlikely

New major risk - Share price stability

Carna Biosciences, Inc. to Report Q2, 2024 Results on Aug 07, 2024

New minor risk - Shareholder dilution

First quarter 2024 earnings released: JP¥23.21 loss per share (vs JP¥32.77 loss in 1Q 2023)

What Carna Biosciences, Inc.'s (TSE:4572) P/S Is Not Telling You

Carna Biosciences, Inc. to Report Q1, 2024 Results on May 10, 2024

Full year 2023 earnings released: JP¥68.57 loss per share (vs JP¥99.07 loss in FY 2022)

Carna Biosciences, Inc., Annual General Meeting, Mar 26, 2024

Carna Biosciences, Inc. to Report Fiscal Year 2023 Results on Feb 09, 2024

Third quarter 2023 earnings released: JP¥20.13 loss per share (vs JP¥31.91 loss in 3Q 2022)

Carna Biosciences, Inc. to Report Q3, 2023 Results on Nov 07, 2023

New minor risk - Market cap size

Second quarter 2023 earnings released: JP¥21.43 loss per share (vs JP¥25.25 loss in 2Q 2022)

Carna Biosciences, Inc. to Report Q2, 2023 Results on Aug 07, 2023

First quarter 2023 earnings released: JP¥32.77 loss per share (vs JP¥1.12 loss in 1Q 2022)

Full year 2022 earnings released: JP¥99.07 loss per share (vs JP¥42.06 loss in FY 2021)

Full year 2022 earnings released: JP¥99.07 loss per share (vs JP¥42.06 loss in FY 2021)

Carna Biosciences, Inc., Annual General Meeting, Mar 24, 2023

Insufficient new directors

Carna Biosciences, Inc. to Report Q4, 2022 Results on Feb 10, 2023

Carna Biosciences, Inc. announced that it has received ¥11.209315 million in funding from Cantor Fitzgerald & Co.

Carna Biosciences, Inc. announced that it expects to receive ¥11.209315 million in funding from Cantor Fitzgerald & Co.

Third quarter 2022 earnings released: JP¥31.91 loss per share (vs JP¥31.70 loss in 3Q 2021)

Carna Biosciences, Inc. to Report Q3, 2022 Results on Nov 07, 2022

Second quarter 2022 earnings released: JP¥25.25 loss per share (vs JP¥39.45 loss in 2Q 2021)

Carna Biosciences, Inc. to Report Q2, 2022 Results on Aug 05, 2022

First quarter 2022 earnings: EPS exceeds analyst expectations

Carna Biosciences, Inc. to Report Q1, 2022 Results on May 10, 2022

Full year 2021 earnings: EPS misses analyst expectations

Carna Biosciences, Inc., Annual General Meeting, Mar 24, 2022

Consensus revenue estimates increase by 40%

Third quarter 2021 earnings released: JP¥31.70 loss per share (vs JP¥20.32 loss in 3Q 2020)

Consensus forecasts updated

Second quarter 2021 earnings released: JP¥39.45 loss per share (vs JP¥17.31 loss in 2Q 2020)

First quarter 2021 earnings released: JP¥23.06 loss per share (vs JP¥15.22 loss in 1Q 2020)

Health Check: How Prudently Does Carna Biosciences (TYO:4572) Use Debt?

Full year 2020 earnings released: JP¥90.33 loss per share (vs JP¥76.03 profit in FY 2019)

How Much Did Carna Biosciences'(TYO:4572) Shareholders Earn From Share Price Movements Over The Last Five Years?

Full year 2020 earnings released: JP¥90.33 loss per share (vs JP¥76.03 profit in FY 2019)

Revenue beats expectations, earnings disappoint

Carna Biosciences, Inc., Annual General Meeting, Mar 25, 2021

New 90-day high: JP¥1,433

Carna Biosciences, Inc. to Report Fiscal Year 2020 Results on Feb 12, 2021

Health Check: How Prudently Does Carna Biosciences (TYO:4572) Use Debt?

New 90-day low: JP¥1,148

Third quarter 2020 earnings released: JP¥20.32 loss per share

New 90-day low: JP¥1,294

Carna Biosciences, Inc. to Report Q3, 2020 Results on Nov 09, 2020

New 90-day low - JP¥1,371

Geschäftsführer

Amtszeit

Führungsteam

Durchschnittliche Betriebszugehörigkeit

Durchschnittliches Alter

Vorstandsmitglieder

Durchschnittliche Betriebszugehörigkeit

Durchschnittliches Alter